Live Trading News
Latest News

Study: COVID Could Be Treated for Less than $1 a Day

By Paul Ebeling2 min read

#COVID #treatment #ivermectin

$MRK

A double-blind study of an antiparasitic drug that’s been in the news a lot lately not only shows that the drug can reduce the duration and infectiousness of COVID-19, but can do all that on less than $1 a day.

That drug is ivermectin, and Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba, says his studies, recently published on RXiv, show it is a cost-effective treatment that can help shorten the infection period. Dr. Schwartz studied 89 volunteers diagnosed with the virus, 50% received ivermectin; the other 50%, a placebo.

Nearly 72% of volunteers treated with ivermectin tested negative for the virus by Day 6,” The Jerusalem Post reported. “In contrast, only 50% of those who received the placebo tested negative.” And, besides feeling better quicker, fewer ivermectin patients also were found to be infectious: 13%, compared to 50% of the placebo group.

The findings also showed that “there is almost a 100% chance that a person will be noninfectious in four to 6 days,” Dr. Schwartz said.

Ivermectin is an inexpensive drug that was approved by the US FDA in Y 1987 for treatment of a parasitic roundworm.

The loudest opposition to ivermectin has come from Merck Co (NYSE:MRK), which manufactured the drug in the 1980s.

In a public statement about ivermectin on its website in February, it said: “Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to date, our analysis has identified no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and a concerning lack of safety data in the majority of studies.”

Merck has not launched any studies of its own on ivermectin.

Have a healthy, prosperous day, Keep the Faith!

Advertisement
Target150
Keep reading
Read Live Trading News on Telegram

Every story, signed and delivered.

Subscribe to the kxco channel and get the headline, the AI-written key takeaways, and the chain-anchor link the moment we publish. Audio versions and per-ticker subscriptions arrive in the next iteration.

Open @KnightsbridgeInsightsNo email required.